Clemens Schulte

1.1k total citations
25 papers, 209 citations indexed

About

Clemens Schulte is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Clemens Schulte has authored 25 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Genetics. Recurrent topics in Clemens Schulte's work include Chemical Synthesis and Analysis (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). Clemens Schulte is often cited by papers focused on Chemical Synthesis and Analysis (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). Clemens Schulte collaborates with scholars based in Germany, United States and France. Clemens Schulte's co-authors include Hans Michael Maric, Thamara Nishida Xavier da Silva, Ariane Nunes‐Alves, José Pedro Friedmann Angeli, Christian A. Olsen, Michael Bæk, Carlos Moreno–Yruela, Carsten P. Ade, Franziska Tippel and Stefan Gaubatz and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Clemens Schulte

21 papers receiving 209 citations

Peers

Countries citing papers authored by Clemens Schulte

Since Specialization

Citations

This map shows the geographic impact of Clemens Schulte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clemens Schulte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clemens Schulte more than expected).

Fields of papers citing papers by Clemens Schulte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clemens Schulte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clemens Schulte. The network helps show where Clemens Schulte may publish in the future.

Co-authorship network of co-authors of Clemens Schulte

This figure shows the co-authorship network connecting the top 25 collaborators of Clemens Schulte. A scholar is included among the top collaborators of Clemens Schulte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clemens Schulte. Clemens Schulte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	eSylites: Synthetic Probes for Visualization and Topographic Mapping of Single Excitatory Synapses 2025 ·Journal of the American Chemical Society ·(unknown), (unknown), Clemens Schulte, (unknown), Katherina Hemmen, Thomas-Otavio Peulen, (unknown), (unknown), (unknown), (unknown), Lars Schönemann, Christian Werner, Hermann Schindelin, Kristian Strømgaard, Carmen Villmann, Katrin G. Heinze, Martin Hruska, Johannes Hell, Hans Michael Maric	0
2	Induction of hepatitis B core protein aggregation targeting an unconventional binding site 2025 ·eLife ·(unknown), (unknown), Clemens Schulte, (unknown), Sonja Kachler, Bettina Böttcher, Hans Michael Maric	1
3	Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study 2025 ·Journal of Cancer Research and Clinical Oncology ·Katrin Schlack, S. Machtens, Thomas Kubin, Markus Ruhnke, Clemens Schulte, (unknown), (unknown), Silke Guenther, Mairead Kearney, Rainer W. Lipp, Stephan Schmitz	0
4	Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 2024 ·Oncogene ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Clemens Schulte, Hans Michael Maric, Carsten P. Ade, Björn von Eyß, Stefan Gaubatz	5
5	Induction of hepatitis B core protein aggregation targeting an unconventional binding site 2024 ·eLife ·(unknown), (unknown), Clemens Schulte, (unknown), Sonja Kachler, Bettina Böttcher, Hans Michael Maric	1
6	Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin 2024 ·Angewandte Chemie ·(unknown), (unknown), (unknown), (unknown), Clemens Schulte, (unknown), (unknown), (unknown), (unknown), Alan Gerber, Hans Michael Maric, Sven Hennig, Tom N. Grossmann	1
7	Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial 2023 ·Annals of Hematology ·Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, (unknown), (unknown), Hans Tesch, (unknown), (unknown), (unknown), Heike L. Pahl	6
8	Molecular characterization of AIFM2/FSP1 inhibition by iFSP1-like molecules 2023 ·Cell Death and Disease ·Thamara Nishida Xavier da Silva, Clemens Schulte, Ariane Nunes‐Alves, Hans Michael Maric, José Pedro Friedmann Angeli	37
9	A Versatile Synthetic Affinity Probe Reveals Inhibitory Synapse Ultrastructure and Brain Connectivity** 2022 ·Angewandte Chemie International Edition ·(unknown), Clemens Schulte, (unknown), Orly Avraham, Cataldo Schietroma, (unknown), (unknown), (unknown), Carmen Villmann, Katrin G. Heinze, Andreas Schlösser, Ora Schueler‐Furman, Philip Tovote, Christian G. Specht, Hans Michael Maric	7
10	Multivalent binding kinetics resolved by fluorescence proximity sensing 2022 ·Communications Biology ·Clemens Schulte, (unknown), Sebastian Spänig, Nathan B. P. Adams, (unknown), Werner Streicher, Dominik Heider, Ralf Strasser, Hans Michael Maric	9
11	Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices 2022 ·Acta Haematologica ·Jolanta Dengler, Hans Tesch, Kathleen Jentsch‐Ullrich, (unknown), Clemens Schulte, (unknown), (unknown), Alexander Kiani	3
12	Peptide Microarray-Based Protein Interaction Studies Across Affinity Ranges: Enzyme Stalling, Cross-Linking, Depletion, and Neutralization 2022 ·Methods in molecular biology ·Clemens Schulte, (unknown), Hans Michael Maric	7
13	Low-cost synthesis of peptide libraries and their use for binding studies via temperature-related intensity change 2021 ·STAR Protocols ·Clemens Schulte, (unknown), (unknown), Hans Michael Maric	11
14	Expanding GABAAR pharmacology via receptor-associated proteins 2021 ·Current Opinion in Pharmacology ·Clemens Schulte, Hans Michael Maric	4
15	Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study 2021 ·Blood ·Steffen Koschmieder, Clemens Schulte, (unknown), Lambert Busque, (unknown), Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, (unknown), Wendy Y. Cheng, (unknown), (unknown), Melody Wu, Mei Sheng Duh, Claire Harrison	0
16	In Vitro Blood–Brain Barrier Permeability and Cytotoxicity of an Atorvastatin-Loaded Nanoformulation Against Glioblastoma in 2D and 3D Models 2020 ·Molecular Pharmaceutics ·Michael M. Lübtow, (unknown), Sabina Quader, Elisabeth Jeanclos, Alevtina Cubukova, (unknown), Malik Salman Haider, Clemens Schulte, (unknown), (unknown), Oltea Sampetrean, Hiroaki Kinoh, Antje Gohla, Kazunori Kataoka, Antje Appelt‐Menzel, Robert Luxenhofer	35
17	Interaction of YAP with the Myb-MuvB (MMB) complex defines a transcriptional program to promote the proliferation of cardiomyocytes 2020 ·PLoS Genetics ·(unknown), Susanne Walz, (unknown), (unknown), (unknown), (unknown), Clemens Schulte, Hans Michael Maric, Carsten P. Ade, Stefan Gaubatz	24
18	High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale 2020 ·iScience ·Clemens Schulte, (unknown), (unknown), Franziska Tippel, (unknown), (unknown), Hans Michael Maric	21
19	CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload 2016 ·Oncology Research and Treatment ·Harald-Robert Bruch, (unknown), (unknown), Gerlinde M. Michl, Rudolf Schlag, (unknown), (unknown), Sebastian Wolf, Clemens Schulte, Hans Tesch	1
20	Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL. 2014 ·Journal of Clinical Oncology ·Douglas E. Gladstone, Marc André, Jan Maciej Zaucha, Sarit Assouline, Naresh Bellam, Nicola Cascavilla, Éric Jourdan, Amit Panwalkar, Caterina Patti, Clemens Schulte, Francesco Zaja, Trishna Goswami, Nairouz Elgeioushi, David Spaner	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact